Institut de la Màcula presents at ARVO the results of the Macbeth Study, conducted with wet AMD patients
Dr. Marc Biarnés, the Coordinator of clinical trials and clinical epidemiology, and Dr. Jordi Monés, the Medical Director of the Institut de la Màcula, have presented a poster devoted to the Macbeth Study at the ARVO 2017 Annual Meeting. They did so on behalf of the Macbeth Study Group, which comprises Roberto Gallego, Ignasi Jürgens, Francisco Cabrera, Laura Sararols, José María Ruiz Moreno, Javier Araiz, Marta Suárez de Figueroa, Carlos Juan Donate and José Luís Olea.
The poster dealt with the results from monitoring the evolution of patients with neovascular AMD (the wet type of the disease) that did not respond satisfactorily to therapy with anti-VEGF-A antibodies and who were treated with aflibercept. The Macbeth Study concluded that after three monthly doses of this injectable, nearly half the patients did not present fluid in optical coherence tomography (OCT). A significant improvement in visual acuity and in central macular thickness (CMT) was also observed. At week 40, one of every 5 patients did not present intraretinal or subretinal fluid and showed a decrease in CMT, with an acceptable safety profile.
At the Meeting, held in Baltimore (United States), the Institut team also learned first hand about the developments in the various treatments for diabetic retinopathy (DR) together with the most important clinical results obtained by the investigators of the Diabetic Retinopathy Clinical Research Network (DRCR.net). The network has a number of clinical trials, both concluded and in progress, that assess treatments for DR and diabetic macular oedema, such as anti-VEGF (Lucentis and Eylea).
To view these results: http://drcrnet.jaeb.org/ViewPage.aspx?PageName=Presentations
The Association for Research in Vision and Ophthalmology (ARVO) is the world’s largest organisation devoted to research into vision.